Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$476.37 USD
-1.33 (-0.28%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $475.02 -1.35 (-0.28%) 6:52 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.37 USD
-1.33 (-0.28%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $475.02 -1.35 (-0.28%) 6:52 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Zacks News
Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More
by Zacks Equity Research
Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.
Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.
Markets Snap Back into Bullish Territory
by Mark Vickery
The Nasdaq led the way, +2.55%, followed by the small-cap Russell 2000, which snapped a five-session losing streak.
Vertex Pharmaceuticals (VRTX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of -5.28% and 2.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data
Another Big Week for Q4 Earnings, Econ News; ON Semi Beats
by Mark Vickery
Q4 earnings season keeps going full-throttle this week, with lots of household names reporting quarterly earnings.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.
Zacks.com featured highlights include: Crocs, AGCO, Meritage Homes and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Crocs, AGCO, Meritage Homes and Vertex Pharmaceuticals
Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.
Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance
by Zacks Equity Research
Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.
Why Earnings Season Could Be Great for Vertex (VRTX)
by Zacks Equity Research
Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Crocs (CROX), AGCO Corporation (AGCO), Meritage Homes (MTH) and Vertex Pharmaceuticals (VRTX) are sound enough to meet financial obligations.
5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.
Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA
by Zacks Equity Research
Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.
Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $241.31, moving +1.57% from the previous trading session.
Top Stock Reports for NIKE, Amgen & Morgan Stanley
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including NIKE (NKE), Amgen (AMGN), and Morgan Stanley (MS).
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics
CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $225.55, marking a -0.25% move from the previous day.
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.